 |
 |
 |
 |
 |
 |
||
 |
 |
 |
 |
 |
| 1 | 1/1 | 返回列表 |
| 查看: 607 | 回復(fù): 0 | |||
[資源]
糖尿病新靶點藥物-SGLT-2抑制劑Dapagliflozin Rejected by F.D.A. Panel
|
|
AstraZeneca and Bristol-Myers Squibb Company today reported the outcome of the US Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on the New Drug Application for the investigational compound dapagliflozin. On the question: "Do the efficacy and safety data provide substantial evidence to support approval of dapagliflozin as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus?", the Advisory Committee voted 6 yes and 9 no. Bristol-Myers Squibb and AstraZeneca remain committed to the dapagliflozin clinical development programme and will continue to work closely with the FDA to support the review of this investigational compound. Dapagliflozin is under joint development by Bristol-Myers Squibb and AstraZeneca. Dapagliflozin is being investigated as monotherapy in addition to diet and exercise, and in combination with other anti-diabetic agents in addition to diet and exercise, to evaluate its effect on blood sugar levels (or HbA1c) in adults with type 2 diabetes. Dapagliflozin, an inhibitor of SGLT2, a target in the kidney, would potentially be the first in a new class of insulin-independent, oral type 2 diabetes agents. The FDA Endocrinologic and Metabolic Drugs Advisory Committee based its voting on a review of data from the comprehensive dapagliflozin global clinical development programme included as part of the FDA New Drug Application submission. This submission included data of up to two years in duration and involved approximately 6,000 individuals in 40 clinical studies. The trials were designed to evaluate the safety, tolerability and efficacy (as measured by HbA1c) of dapagliflozin in the approximately 4,200 patients who received dapagliflozin and were at various stages of the continuum of type 2 diabetes. In accordance with FDA guidelines, the New Drug Application also included data assessing the cardiovascular safety of dapagliflozin in adults with type 2 diabetes. The FDA is not bound by the Advisory Committee's recommendation but takes its advice into consideration when reviewing New Drug Applications. The Prescription Drug User Fee Act (PDUFA) goal date for dapagliflozin is 28 October 2011. NOTES TO EDITORS About Type 2 Diabetes In 2010, diabetes was estimated to affect nearly 300 million people aged 20 - 79 worldwide. Because of the aging population and the growing trend of obesity, the prevalence of diabetes is projected to reach nearly 440 million by 2030. Type 2 diabetes accounts for approximately 90 - 95% of all cases of diagnosed diabetes in adults. Type 2 diabetes is a chronic, progressive disease characterised by insulin resistance and/or dysfunction of beta cells in the pancreas, which decreases insulin sensitivity and secretion, leading to elevated glucose levels. Over time, this sustained hyperglycemia contributes to worsening insulin resistance and further beta cell dysfunction. To date, treatments for type 2 diabetes have focused primarily on insulin-dependent mechanisms. An approach that acts independently of insulin could provide an additional option for adults with type 2 diabetes. Significant unmet needs exist as nearly half of treated patients remain uncontrolled on their current glucose-lowering regimen. Many patients with type 2 diabetes have additional co-morbidities (such as obesity) which may complicate glycemic control. About SGLT2 Inhibition The kidney plays an important role in glucose balance, normally filtering ~180g of glucose each day, with virtually all glucose being reabsorbed back into circulation. SGLT2 is the major sodium-glucose cotransporter in the kidney and is an insulin-independent pathway for the reabsorption of glucose back into the blood. 、 |
回復(fù)此樓» 猜你喜歡
是不是現(xiàn)在考博都是推薦制？或者是已經(jīng)內(nèi)定了？還有通過考試招博士的學(xué)校嗎？
已經(jīng)有39人回復(fù)
-
農(nóng)產(chǎn)品中農(nóng)藥監(jiān)測的免疫傳感器的疑問
已經(jīng)有0人回復(fù)
-
藥理學(xué)論文潤色/翻譯怎么收費?
已經(jīng)有165人回復(fù)
-
納米傳感器監(jiān)測農(nóng)藥殘留的疑惑
已經(jīng)有0人回復(fù)
-
誰有人衛(wèi)版 《毒理學(xué)基礎(chǔ)》第七版書籍
已經(jīng)有0人回復(fù)
-
26有沒有老師想收做定量藥理的學(xué)生啊
已經(jīng)有3人回復(fù)
-
26考博申請 學(xué)or專
已經(jīng)有15人回復(fù)
找到一些相關(guān)的精華帖子，希望有用哦~
【課件】天然藥物化學(xué)（華中科技大學(xué)）
已經(jīng)有275人回復(fù)
- 博士點基金的到賬時間
已經(jīng)有6人回復(fù)
- 要不要轉(zhuǎn)2+3博士 藥物化學(xué)專業(yè)
已經(jīng)有15人回復(fù)
- 有機合成，藥物化學(xué)，文章影響因子數(shù)
已經(jīng)有15人回復(fù)
- 【習(xí)題資源】藥物化學(xué)習(xí)題
已經(jīng)有54人回復(fù)
- 分子靶向抗腫瘤藥物研究進展
已經(jīng)有188人回復(fù)
- 【納米醫(yī)學(xué)】夏幼南最新一篇關(guān)于靶向藥物的報道
已經(jīng)有119人回復(fù)
點擊這里搜索更多相關(guān)資源科研從小木蟲開始，人人為我，我為人人
相關(guān)版塊跳轉(zhuǎn)
我要訂閱樓主 091602 的主題更新
| 1 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 297 地理學(xué)070500 復(fù)試求調(diào)劑 +3 | 小圓圈圈ooo 2026-03-30 | 3/150 |
|
|---|---|---|---|---|
|
|
[考研] 085600 286分 材料求調(diào)劑 +11 | 麻辣魷魚 2026-03-27 | 12/600 |
|
|
[考研] 297求調(diào)劑 +17 | 田洪有 2026-03-26 | 18/900 |
|
|
|
[考研] 化學(xué)0703 調(diào)劑 306分 一志愿211 +8 | 26要上岸 2026-03-28 | 8/400 |
|
|
|
[考研] 0703化學(xué)/290求調(diào)劑/本科經(jīng)歷豐富/工科也可 +13 | 丹青奶蓋 2026-03-26 | 15/750 |
|
|
|
[考研] 318一志愿吉林大學(xué)生物與醫(yī)藥 求調(diào)劑 +5 | 篤行致遠. 2026-03-28 | 5/250 |
|
|
|
[考研] 一志愿北京工業(yè)大學(xué)，324分求調(diào)劑 +6 | 零八# 2026-03-28 | 6/300 |
|
|
|
[考研] 343求調(diào)劑 +6 | 愛羈絆 2026-03-29 | 6/300 |
|
|
|
[考研] 調(diào)劑考研 +3 | 王杰一 2026-03-29 | 3/150 |
|
|
|
[考研] 312，生物學(xué)求調(diào)劑 +3 | 小譯同學(xué)abc 2026-03-28 | 3/150 |
|
|
|
[考研] 材料與化工（0856）304求B區(qū)調(diào)劑 +8 | 邱gl 2026-03-27 | 8/400 |
|
|
|
[考研] 085602 307分 求調(diào)劑 +7 | 不知道叫什么！ 2026-03-26 | 7/350 |
|
|
|
[考研] 一志愿上海理工能源動力（085800）310分求調(diào)劑 +3 | zhangmingc 2026-03-27 | 4/200 |
|
|
|
[考研] 279 分 求調(diào)劑 +4 | 睡個好覺_16 2026-03-24 | 4/200 |
|
|
|
[考研] 08開頭275求調(diào)劑 +4 | 拉誰不重要 2026-03-26 | 4/200 |
|
|
|
[考研] 085601 材料工程 313分 求調(diào)劑 +5 | Ong3 2026-03-27 | 5/250 |
|
|
|
[考研] 考研調(diào)劑 +10 | 呼呼？~+123456 2026-03-24 | 10/500 |
|
|
|
[考研] 314求調(diào)劑 +3 | 溪云珂 2026-03-26 | 3/150 |
|
|
|
[考研] 285求調(diào)劑 +3 | AZMK 2026-03-24 | 3/150 |
|
|
|
[考研] 調(diào)劑 +4 | 13853210211 2026-03-24 | 4/200 |
|